About
About Universal Biosensors, Inc
Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also provides non-diagnostic laboratory services and coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a test strip and a meter to be used for the detection and monitoring of diabetes in non-humans. Universal Biosensors, Inc. was incorporated in 2001 and is based in Rowville, Australia.
Visit company website
5 years, 5 months ago
Universal Biosensors, Inc is currently in a long term uptrend where the price is trading 71.6% above its 200 day moving average.
From a valuation standpoint, the stock is 89.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 27.4.
Universal Biosensors, Inc's total revenue rose by 14.6% to $2M since the same quarter in the previous year.
Its net income has dropped by 87.9% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 102.8% to $203K since the same quarter in the previous year.
Based on the above factors, Universal Biosensors, Inc gets an overall score of 4/5.